All RA and SpA patients were classified into six groups according to their treatments: csDMARDs monotherapy (MTX: n=17; sulfasalazine: n=2) (median age of 65±15 years); anti-TNF monotherapy (n=24, median age of 43.5±15 years); anti-TNF combotherapy (n=23, median age of 56±13 years); rituximab (RTX), only one patient with RTX without MTX (n=11, median age of 55±11 years); anti-IL17 treatments (n=7, median age of 54±13 years). This evidence concerns the gene IL17A and rheumatoid arthritis.